Proliferation through activation: Hemophagocytic lymphohistiocytosis in hematologic malignancy

Blood Advances

Volumn 1, Issue 12, 2017, Pages 779-791

  Vick, Eric J ^a   Patel, Kruti ^b   Prouet, Philippe ^c   Martin, Mike G ^c  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Medical Oncology Hematology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056613315     PISSN: 24739529     EISSN: 24739537     Source Type: Journal    
DOI: 10.1182/bloodadvances.2017005561     Document Type: Review

References (117)

1. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
2. Clementi R, zur Stadt U, Savoldi G, et al. Six novel mutations in the PRF1 gene in children with haemophagocytic lymphohistiocytosis. J Med Genet. 2001;38(9):643-646.
3. Voskoboinik I, Thia M-C, Trapani JA. A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. Blood. 2005;105(12):4700-4706.
4. Rosado FGN, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139(6):713-727.
5. Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis. Arch Dis Child. 1952;27(136):519-525.
6. Henter J-I, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
7. Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol. 2013;161(5):609-622.
8. Podack ER, Munson GP. Killing of microbes and cancer by the immune system with three mammalian pore-forming killer proteins. Front Immunol. 2016;7:464.
9. Lee S-H, Kim K-S, Fodil-Cornu N, Vidal SM, Biron CA. Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection. J Exp Med. 2009;206(10):2235-2251.
10. La Cava A, Van Kaer L, Fu-Dong-Shi. CD41CD251 Tregs and NKT cells: regulators regulating regulators. Trends Immunol. 2006;27(7):322-327.
11. Ishii E. Hemophagocytic lymphohistiocytosis in children: pathogenesis and treatment. Front Pediatr. 2016;4:47.
12. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957-1959.
13. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115(4):461-473.
14. zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14(6):827-834.
15. Côte M, Ménager MM, Burgess A, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest. 2009;119(12):3765-3773.
16. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26(3):263-280.
17. Nagai K, Ochi F, Terui K, et al. Clinical characteristics and outcomes of Chédiak-Higashi syndrome: a nationwide survey of Japan. Pediatr Blood Cancer. 2013;60(10):1582-1586.
18. Meeths M, Bryceson YT, Rudd E, et al. Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr Blood Cancer. 2010;54(4):563-572.
19. Jessen B, Bode SFN, Ammann S, et al. The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2. Blood. 2013;121(15): 2943-2951.
20. Pachlopnik Schmid J, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117(5):1522-1529.
21. Tesi B, Sieni E, Neves C, et al. Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-g receptor deficiency. J Allergy Clin Immunol. 2015;135(6):1638-1641.
22. Ghosh S, Bienemann K, Boztug K, Borkhardt A. Interleukin-2-inducible T-cell kinase (ITK) deficiency - clinical and molecular aspects. J Clin Immunol. 2014;34(8):892-899.
23. Eife R, Janka GE, Belohradsky BH, Holtmann H. Natural killer cell function and interferon production in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol. 1989;6(3):265-272.
24. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.
25. Hayden A, Park S, Giustini D, Lee AYY, Chen LYC. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. Blood Rev. 2016;30(6):411-420.
26. Lim SH, Park S, Jang JH, et al. Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. Ann Hematol. 2016;95(2):325-335.
27. Bracaglia C, de Graaf K, Pires Marafon D, et al. Elevated circulating levels of interferon-g and interferon-g-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76(1):166-172.
28. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine. 2008;43(3):374-379.
29. Tiong IS, Lau MBY, Toumoua S, Chiruka S. A case of hemophagocytic lymphohistiocytosis in a patient with chronic lymphocytic leukemia after treatment with fludarabine, cyclophosphamide, and rituximab chemotherapy, with autopsy findings. Case Rep Hematol. 2012;2012:326053.
30. Janka GE, Lehmberg K. Hemophagocytic syndromes–an update. Blood Rev. 2014;28(4):135-142.
31. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048]. Blood. 2014;124(2):188-195.
32. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1b in autoinflammatory diseases. Arthritis Rheum. 2011;63(2):314-324.
33. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-545.
34. Sepehrizadeh Z, Mohammadi M, Emami A, et al. Assessment of cytokine expression profile in acute myeloid leukemia patients before and after chemotherapy. Turk J Haematol. 2014;31(2):149-154.
35. Yamamoto T, Kimura T, Ueta E, Tatemoto Y, Osaki T. Characteristic cytokine generation patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns. Oncology. 2003;64(4):407-415.
36. Jayakody Arachchillage D, Hurst E, Carey P, et al. Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia. Br J Haematol. 2014;166(1):142-145.
37. Nascimento FA, Nery J, Trennepohl J, Pianovski MAD. Hemophagocytic lymphohistiocytosis after initiation of chemotherapy for bilateral adrenal neuroblastoma. J Pediatr Hematol Oncol. 2016;38(1):e13-e15.
38. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD81 T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735-743.
39. Binder D, van den Broek MF, Kägi D, et al. Aplastic anemia rescued by exhaustion of cytokine-secreting CD81 T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp Med. 1998;187(11):1903-1920.
40. Pachlopnik Schmid J, Ho C-H, Chrétien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27adeficient mice. EMBO Mol Med. 2009;1(2):112-124.
41. Tiwari S, Hontz A, Terrell CE, et al. High level of perforin expression is required for effective correction of hemophagocytic lymphohistiocytosis [published online ahead of print 29 July 2016]. Hum Gene Ther. doi:10.1089/hum.2016.065.
42. Xu X-J, Tang Y-M, Song H, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012; 160(6):984-90.e1.
43. Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(1) T cells and dendritic cells. Blood. 2013; 121(26):5184-5191.
44. López-Alvarez MR, Martínez-Sánchez MV, Salgado-Cecilia MG, et al. Association of monoclonal expansion of Epstein-Barr virus-negative CD158a1 NK cells secreting large amounts of gamma interferon with hemophagocytic lymphohistiocytosis. Clin Vaccine Immunol. 2009;16(1):142-145.
45. Brady MT, Lee J, Ferrone S, Wang ES, Wetzler M. Interferon-g secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. Leuk Res. 2011; 35(2):275-277.
46. Tesi B, Lagerstedt-Robinson K, Chiang SCC, et al. Targeted high-throughput sequencing for genetic diagnostics of hemophagocytic lymphohistiocytosis. Genome Med. 2015;7:130.
47. Leifer CA, Medvedev AE. Molecular mechanisms of regulation of Toll-like receptor signaling. J Leukoc Biol. 2016;100(5):927-941.
48. Krebs P, Crozat K, Popkin D, Oldstone MB, Beutler B. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood. 2011;117(24):6582-6588.
49. Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011; 121(6):2264-2277.
50. Monlish DA, Bhatt ST, Schuettpelz LG. The role of Toll-like receptors in hematopoietic malignancies. Front Immunol. 2016;7(390):390.
51. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010;16(1):49-58.
52. Mollaki V, Georgiadis T, Tassidou A, et al. Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin’s lymphoma: a candidate-gene association study. J Hum Genet. 2009;54(11):655-659.
53. Rybka J, Butrym A, Wróbel T, et al. The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy. Leuk Res. 2015;39(3):318-322.
54. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119.
55. Bronk CC, Yoder S, Hopewell EL, et al. NF-kB is crucial in proximal T-cell signaling for calcium influx and NFAT activation. Eur J Immunol. 2014;44(12): 3741-3746.
56. Chuang H-C, Lay J-D, Hsieh W-C, Su I-J. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target. Cancer Sci. 2007;98(9):1281-1287.
57. O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161-170.
58. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282(28):20059-20063.
59. O’Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109(Suppl):S121-S131.
60. Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127(13):1666-1675.
61. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-g-producing lymphocytes and IL-6- and TNF-a-producing macrophages. Blood. 2005;105(4):1648-1651.
62. Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89(11): 4100-4103.
63. Yang C, Zhang D-M, Song Z-B, et al. Protumoral TSP50 regulates macrophage activities and polarization via production of TNF-a and IL-1b, and activation of the NF-kB signaling pathway. PLoS One. 2015;10(12):e0145095.
64. Weber J, Yang JC, Topalian SL, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993;11(3):499-506.
65. Créput C, Galicier L, Buyse S, Azoulay E. Understanding organ dysfunction in hemophagocytic lymphohistiocytosis. Intensive Care Med. 2008;34(7):1177-1187.
66. Biet F, Locht C, Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med (Berl). 2002; 80(3):147-162.
67. Nold-Petry CA, Lehrnbecher T, Jarisch A, et al. Failure of interferon g to induce the anti-inflammatory interleukin 18 binding protein in familial hemophagocytosis. PLoS One. 2010;5(1):e8663.
68. Sepulveda FE, Maschalidi S, Vosshenrich CAJ, et al. A novel immunoregulatory role for NK-cell cytotoxicity in protection from HLH-like immunopathology in mice. Blood. 2015;125(9):1427-1434.
69. Takada H, Ohga S, Mizuno Y, Nomura A, Hara T. Increased IL-16 levels in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2004;26(9):567-573.
70. Tamura K, Kanazawa T, Tsukada S, Kobayashi T, Kawamura M, Morikawa A. Increased serum monocyte chemoattractant protein-1, macrophage inflammatory protein-1beta, and interleukin-8 concentrations in hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;51(5):662-668.
71. Hanoun M, Dührsen U. The maze of diagnosing hemophagocytic lymphohistiocytosis: single-center experience of a series of 6 clinical cases. Oncology. 2017;92(3):173-178.
72. Debaugnies F, Mahadeb B, Ferster A, et al. Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients. Am J Clin Pathol. 2016;145(6):862-870.
73. Wang H-Y, Yang C-F, Chiou T-J, et al. Risk of hemophagocytic lymphohistiocytosis in adults with fevers of unknown origin: the clinical utility of a new scoring system on early detection [published online ahead of print 28 July 2016]. Hematol Oncol. doi:10.1002/hon.2333.
74. Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H. A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol. 2014;93(5):821-826.
75. Chen W, Zhang S, Zhang W, et al. Elevated serum adenosine deaminase levels in secondary hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 2015;37(4):544-550.
76. Chung HJ, Park CJ, Lim JH, et al. Establishment of a reference interval for natural killer cell activity through flow cytometry and its clinical application in the diagnosis of hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 2010;32(2):239-247.
77. Grossman WJ, Radhi M, Schauer D, Gerday E, Grose C, Goldman FD. Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8. Blood. 2005;106(4):1203-1206.
78. Cattaneo C, Oberti M, Skert C, et al. Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients [published online ahead of print 3 June 2016]. Hematol Oncol. doi:10.1002/hon.2314.
79. Re A, Facchetti F, Borlenghi E, et al. Fatal hemophagocytic syndrome related to active human herpesvirus-8/Kaposi sarcoma-associated herpesvirus infection in human immunodeficiency virus-negative, non-transplant patients without related malignancies. Eur J Haematol. 2007;78(4):361-364.
80. Patel K, Lee SS, Valasareddy P, Vontela NR, Prouet P, Martin MG. Genetic analysis of B-cell lymphomas associated with hemophagocytic lymphohistiocytosis. Blood Adv. 2016;1:205-207.
81. Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol. 2015;168(1):63-68.
82. Li J, Wang Q, Zheng W, et al. Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine (Baltimore). 2014;93(2):100-105.
83. Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220-224.
84. Sano H, Kobayashi R, Tanaka J, et al. Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study. Br J Haematol. 2014;165(6):786-792.
85. Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014;192(1):84-91.
86. Henter J-I, Samuelsson-Horne A, Aricò M, et al; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367-2373.
87. Trottestam H, Horne A, Aricò M, et al; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577-4584.
88. Fischer A, Cerf-Bensussan N, Blanche S, et al. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J Pediatr. 1986; 108(2):267-270.
89. Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol. 2010;7(7):415-420.
90. Weitzman S. Approach to hemophagocytic syndromes. Hematology Am Soc Hematol Educ Program. 2011;2011:178-183.
91. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19(10):2665-2673.
92. Johnson B, Giri S, Nunnery SE, et al. Comorbidities drive outcomes for both malignancy-associated and non-malignancy-associated hemophagocytic syndrome. Clin Lymphoma Myeloma Leuk. 2016;16(4):230-236.
93. Yu J-T, Wang C-Y, Yang Y, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol. 2013;92(11):1529-1536.
94. Mahlaoui N, Ouachée-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007;120(3):e622-e628.
95. Olin RL, Nichols KE, Naghashpour M, et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol. 2008;83(9):747-749.
96. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101-109.
97. Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol. 2006;81(1):59-61.
98. Oda Y, Urushidani Y, Ooi S, et al. Hemophagocytic lymphohistiocytosis in a rheumatoid arthritis patient treated with infliximab. Intern Med. 2012;51(6):655-657.
99. Wang Y-R, Qiu Y-N, Bai Y, Wang X-F. A retrospective analysis of 56 children with hemophagocytic lymphohistiocytosis. J Blood Med. 2016;7:227-231.
100. Xu X-J, Wang H-S, Ju X-L, et al; Histiocytosis Study Group of the Chinese Pediatric Society. Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China: a retrospective multicenter study. Pediatr Blood Cancer. 2017;64(4):e26264.
101. Kaya Z, Bay A, Albayrak M, Kocak U, Yenicesu I, Gursel T. Prognostic factors and long-term outcome in 52 Turkish children with hemophagocytic lymphohistiocytosis. Pediatr Crit Care Med. 2015;16(6):e165-e173.
102. Koh KN, Im HJ, Chung NG, et al; Korea Histiocytosis Working Party. Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in Korea: report of a nationwide survey from Korea Histiocytosis Working Party. Eur J Haematol. 2015;94(1):51-59.
103. Grangé S, Buchonnet G, Besnier E, et al. The use of ferritin to identify critically ill patients with secondary hemophagocytic lymphohistiocytosis. Crit Care Med. 2016;44(11):e1045-e1053.
104. Bin Q, Gao J-H, Luo J-M. Prognostic factors of early outcome in pediatric hemophagocytic lymphohistiocytosis: an analysis of 116 cases. Ann Hematol. 2016;95(9):1411-1418.
105. Jiang T, Ding X, Lu W. The prognostic significance of Beta2 microglobulin in patients with hemophagocytic lymphohistiocytosis. Dis Markers. 2016;2016:1523959.
106. Dalal BI, Vakil AP, Khare NS, Wang SY, Richards MJ, Chen LY. Abnormalities of the lymphocyte subsets and their immunophenotype, and their prognostic significance in adult patients with hemophagocytic lymphohistiocytosis. Ann Hematol. 2015;94(7):1111-1117.
107. Xiao L, Xian Y, Dai BT, et al. Clinical features and outcome analysis of 83 childhood Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with HLH-2004 protocol [in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2011;32(10):668-672.
108. Li YG, Mao YN, Liu W, et al. Analysis of prognostic risk factors in childhood hemophagocytic syndrome [in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2011; 32(12):836-839.
109. My LT, Lien B, Hsieh W-C, et al. Comprehensive analyses and characterization of haemophagocytic lymphohistiocytosis in Vietnamese children. Br J Haematol. 2010;148(2):301-310.
110. Jenkins RW, Clarke CJ, Lucas JT Jr, et al. Evaluation of the role of secretory sphingomyelinase and bioactive sphingolipids as biomarkers in hemophagocytic lymphohistiocytosis. Am J Hematol. 2013;88(11):E265-E272.
111. Xue H, Chen C, Li W, et al. Analysis of prognostic risk factors in children with Epstein-Barr virus-associated hemophagocytic syndrome. Minerva Pediatr. 2015;67(3):251-261.
112. Zheng Y, Hu G, Liu Y, et al. The role of (18)F-FDG PET/CT in the management of patients with secondary haemophagocytic lymphohistiocytosis. Clin Radiol. 2016;71(12):1248-1254.
113. Yoon HS, Im HJ, Moon HN, et al. The outcome of hematopoietic stem cell transplantation in Korean children with hemophagocytic lymphohistiocytosis. Pediatr Transplant. 2010;14(6):735-740.
114. Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126(19):2186-2192.
115. Jing-Shi W, Yi-Ni W, Lin W, Zhao W. Splenectomy as a treatment for adults with relapsed hemophagocytic lymphohistiocytosis of unknown cause. Ann Hematol. 2015;94(5):753-760.
116. Zhou X, Dotti G, Krance RA, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015;125(26):4103-4113.
117. Shin H-J, Chung JS, Lee J-J, et al. Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci. 2008;23(3):439-444.